Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Gut Microbes. 2023 Jan-Dec;15(1):2195792. doi: 10.1080/19490976.2023.2195792.
Reliable biomarkers for common disorders of gut-brain interaction characterized by abdominal pain, including irritable bowel syndrome (IBS), are critically needed to enhance care and develop individualized therapies. The dynamic and heterogeneous nature of the pathophysiological mechanisms that underlie visceral hypersensitivity have challenged successful biomarker development. Consequently, effective therapies for pain in IBS are lacking. However, recent advances in modern omics technologies offer new opportunities to acquire deep biological insights into mechanisms of pain and nociception. Newer methods for large-scale data integration of complementary omics approaches have further expanded our ability to build a holistic understanding of complex biological networks and their co-contributions to abdominal pain. Here, we review the mechanisms of visceral hypersensitivity, focusing on IBS. We discuss candidate biomarkers for pain in IBS identified through single omics studies and summarize emerging multi-omics approaches for developing novel biomarkers that may transform clinical care for patients with IBS and abdominal pain.
可靠的生物标志物对于以腹痛为特征的常见肠脑相互作用障碍（包括肠易激综合征[IBS]）至关重要，这有助于改善治疗并开发个体化疗法。内脏高敏反应的病理生理机制具有动态和异质性，这给成功开发生物标志物带来了挑战。因此，IBS 疼痛的有效治疗方法仍然缺乏。然而，现代组学技术的最新进展为深入了解疼痛和伤害感受机制提供了新的机会。补充组学方法的大规模数据整合的新方法进一步扩大了我们构建复杂生物网络及其对腹痛共同贡献的整体理解的能力。在这里，我们回顾了内脏高敏反应的机制，重点是 IBS。我们讨论了通过单一组学研究确定的 IBS 疼痛候选生物标志物，并总结了新兴的多组学方法，这些方法可能为开发新的生物标志物提供了新的机会，从而改变 IBS 和腹痛患者的临床护理。
